chromosome 10 open reading frame 105Genealiases: []
Q-omics provides the consensus-scored C10orf105 profile across patient tissues and cancer cell-line models. C10orf105 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, C10orf105 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, C10orf105 RNA expression shows 12,351 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where C10orf105 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C10orf105 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C10orf105 survival associations across molecular data types. C10orf105 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C10orf105 RNA expression–survival associations across cancer types. High C10orf105 expression shows unfavorable associations in UVM, LGG and LAML, but favorable associations in HNSC, KIRC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for C10orf105 RNA expression.
This table summarizes C10orf105 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for C10orf105. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C10orf105 shows lower tumor expression in COAD, LUAD, LUSC, BLCA and UCEC and higher tumor expression in KIRC. The COAD box plot shows higher C10orf105 RNA expression in normal versus tumor tissue (log2 FC = −0.144, t-test p < 0.001).
This table shows molecular features associated with C10orf105 in patient tissues and cancer cell lines. In patient samples, C10orf105 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, C10orf105 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
